Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 240

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 240
---
 The market price of the combined company’s common stock following the Merger could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of the combined company’s common stock to fluctuate include:

| ● | the ability of the combined company to obtain regulatory approvals for its product candidates, and delays or failures to obtain such approvals; |

| ● | failure of any of the combined company’s product candidates, if approved, to achieve commercial success; |

| ● | failure by the combined company to maintain its existing third-party license and supply agreements; |

| ● | failure by the combined company or its licensors to prosecute, maintain, or enforce its intellectual property rights; |

| ● | changes in laws or regulations applicable to the combined company’s product candidates; |

| ● | any inability to obtain adequate supply of the combined company’s product candidates or the inability to do so at acceptable prices; |

| ● | adverse regulatory authority decisions; |

| ● | introduction of new products, services or technologies by the combined company’s competitors; |

| ● | failure to meet or exceed financial and development projections the combined company may provide to the public; |

| ● | failure to meet or exceed the financial and development projections of the investment community; |

| ● | the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; |

| ● | announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors; |

| ● | disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company’s ability to obtain patent protection for its technologies; |

| ● | additions or departures of key personnel; |

| ● | significant lawsuits, including patent or stockholder litigation; |

| ● | if securities or industry analysts do not publish research or reports about the combined company’s business, or if they issue an adverse or misleading opinion regarding its business and stock; |

| ● | changes in the market valuations of similar companies; |

| ● | general market or macroeconomic conditions; |

| ● | sales of its common stock by the combined company or its stockholders in the future; |

124

| ● | trading volume of the combined company’s common stock; |

| ● | failure to maintain compliance with the listing requirements of The Nasdaq Capital Market; |

| ● | announcements by commercial partners or competitors of new commercial products